Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $264.9 million.

  • Ani Pharmaceuticals' Cash from Financing Activities fell 97.82% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 103.96%. This contributed to the annual value of $264.9 million for FY2024, which is 292.87% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Cash from Financing Activities of $264.9 million as of FY2024, which was up 292.87% from $67.4 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Cash from Financing Activities ranged from a high of $264.9 million in FY2024 and a low of -$5.1 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $67.4 million (2023), whereas its average is $109.1 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Cash from Financing Activities tumbled by 215.12% in 2020, and later skyrocketed by 13,622.93% in 2021.
  • Ani Pharmaceuticals' Cash from Financing Activities (Yearly) stood at -$1.4 million in 2020, then surged by 13,622.93% to $194.6 million in 2021, then plummeted by 102.63% to -$5.1 million in 2022, then skyrocketed by 1,415.63% to $67.4 million in 2023, then spiked by 292.87% to $264.9 million in 2024.